| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -18,248 | -26,510 | -14,229 | 23,371 |
| Amortization of intangible assets | 37 | 37 | 36 | 73 |
| Depreciation and amortization | 214 | 473 | 98 | 659 |
| Impairment loss on machinery and equipment | NaN | -402 | NaN | NaN |
| Accretion of discounts on short-term investments | 726 | 719 | 636 | 851 |
| Stock-based compensation expense | 4,706 | 1,479 | 1,384 | 3,439 |
| Non-cash lease expense | -1,132 | -1,161 | -1,133 | -2,189 |
| Accounts receivable | -1,367 | 384 | -240 | -1,234 |
| Prepaid expenses and other assets | 887 | 874 | -708 | 1,076 |
| Accounts payable | 67 | 655 | 419 | -853 |
| Accrued liabilities and other long-term liabilities | -3,599 | 486 | -326 | -3,209 |
| Deferred revenue | -9,612 | 551 | -4,375 | -61,772 |
| Net cash used in operating activities | -25,549 | -23,243 | -15,548 | -36,796 |
| Purchases of property and equipment | 0 | 201 | -127 | 146 |
| Purchases of short-term investments | 242,777 | 44,218 | 19,688 | 128,618 |
| Maturities of short-term investments | 50,000 | 30,000 | 20,000 | 83,000 |
| Net cash (used in) provided by investing activities | -192,777 | -14,419 | 439 | -45,764 |
| Proceeds from issuance of common stock, net issuance cost | 228,351 | 16,262 | 0 | 93,373 |
| Proceeds from issuance of pre-funded warrants, net issuance cost | 5,855 | 0 | NaN | NaN |
| Proceeds from exercise of stock options | 281 | 381 | 253 | 177 |
| Net cash provided by financing activities | 234,487 | 16,643 | 253 | 93,550 |
| Net increase in cash, cash equivalents and restricted cash | 16,161 | -21,019 | -14,856 | 10,990 |
| Cash, cash equivalents and restricted cash, beginning of period | 14,194 | 35,213 | 39,079 | NaN |
| Cash, cash equivalents and restricted cash, end of period | 30,355 | 14,194 | 35,213 | NaN |
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)